25.06.2024
Diese Studie liefert einige interessante Erkenntnisse:
Our findings suggest that SARS-CoV-2 vaccination may not provide enduring protection against severe disease, preventing us from confirming our initial hypothesis. Furthermore, we observed that patients who received three vaccine doses were more likely to develop severe symptoms. However, as the remaining vaccinated groups (1 or 2 vaccine shots) did not show an elevated risk for severe disease compared to unvaccinated adults, this finding should be interpreted cautiously. To gain a more comprehensive understanding of the vaccine’s effects in the endemic phase of COVID-19, further research with a larger sample size is imperative.
The presented results underscore that specific patient-related factors, especially age and the presence of pre-existing chronic conditions, significantly contribute to an elevated risk of encountering severe cases of COVID-19 during the endemic phase of the illness. The association between advancing age and the presence of chronic diseases with an escalated risk of severe disease has been widely documented throughout the entire course of the pandemic’s progression.
D.h. in der an die Pandemie anschließende endemische Phase liefern die Impfungen keinen wirklichen Vorteil mehr, hinsichtlich schwerer Covid-Verläufe. Dreifachgeimpfte haben sogar ein geringfügig höheres Risko für schwere Verlaufe. Wobei die Autoren darauf hinweisen, dass patientenspezifische Faktoren (Alter, Vorerkrankungen) einen erheblichen Amteil und Einfluß auf die Schwere der Krankheitsverläufe haben. Besonders dieser (Risiko)Personengruppe wurden aber Boosterimpfungen besonders empfohlen.
Ebenfalls interessant:
Ergebnisse kurz zusammengefasst:
Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection.
Inklusive der frühen Delta-Infelktionswelle bieten 2fache Impfung und jede Form von hybrider Immunisierung (geimpft + genesen) einen wirkungsvollen Schutz vor schweren Covidverläufen. DIe Autoren bewerten Impfungen als den sichersten Weg für einen (Infektions)Schutz.
We conducted a quantitative BR assessment of COVID-19 vaccines using the MCDA and showed the rank of preferred vaccines based on evidence before and after approval. Before approval, mRNA-1273 ranked the highest, followed by ChAdOx1-S, BNT162b2, and Ad26.COV.2. After approval, BNT162b2 ranked the highest, followed by mRNA-1273, with a 1.0-point difference. [...]
We found that mRNA-based vaccines were preferred before and after approval.
In einer systematischen Risikobewertung vor und nach Zulassung schnitten die mRNA basierenden Impfstoff jeweils am besten ab. Und ausgerechnet der hier im Forum immer wieder angegriffene Impfstoff von BioNTech/Pfizzer nimmt dabei die Spitzenposition ein.
Results
Participants included 99,068,901 vaccinated individuals. In total, 183,559,462 doses of BNT162b2, 36,178,442 doses of mRNA-1273, and 23,093,399 doses of ChAdOx1 were administered across participating sites in the study period. Risk periods following homologous vaccination schedules contributed 23,168,335 person-years of follow-up. OE ratios with LBCI > 1.5 were observed for Guillain-Barré syndrome (2.49, 95 % CI: 2.15, 2.87) and cerebral venous sinus thrombosis (3.23, 95 % CI: 2.51, 4.09) following the first dose of ChAdOx1 vaccine. Acute disseminated encephalomyelitis showed an OE ratio of 3.78 (95 % CI: 1.52, 7.78) following the first dose of mRNA-1273 vaccine. The OE ratios for myocarditis and pericarditis following BNT162b2, mRNA-1273, and ChAdOx1 were significantly increased with LBCIs > 1.5.
Conclusion
This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified.
Der Impfstoff ChAdOx1 (Vektor-Impfstoff von AstraZeneca) hat hier das höchste Nebenwirkungspotential, speziell hinsichtlich Guillain-Barré-Syndrom und Sinusvenenthrombosen.
Ebenfalls nicht unproblematisch ist der Impfstoff mRNA-1273 (Spikevax von Moderna) hinsichtlich Encephalomyolitis.
Der mRNA Impfstoff BNT162b2 (BioNTeh) taucht hierbei nur in der Kathegorie Myc-/Pericarditis auf.
Hir die Übersicht über OE (observed versus expected ratios) und die dazugehörende statistische Relevanz:
Auch hier schneidet das "Feindbild" der QD, der mRNA Impfstoff von BioNTech vergleichsweise gut, in vielen Kathegorien am besten (=risikoärmsten) ab.
Was diesem Vergleich jetzt noch fehlt, wären die entsprechenden Risiken durch eine Covid-19-Infektion...
